GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) - Investment analysts at HC Wainwright issued their FY2025 earnings per share estimates for GENFIT in a research report issued on Tuesday, August 19th. HC Wainwright analyst B. Folkes expects that the company will post earnings of $0.01 per share for the year. HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for GENFIT's current full-year earnings is $0.95 per share. HC Wainwright also issued estimates for GENFIT's FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.24) EPS, FY2028 earnings at ($0.90) EPS and FY2029 earnings at ($0.64) EPS.
GENFIT Stock Performance
NASDAQ GNFT traded down $0.15 during trading on Thursday, hitting $4.08. 1,049 shares of the company's stock were exchanged, compared to its average volume of 8,640. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.08. GENFIT has a fifty-two week low of $2.55 and a fifty-two week high of $6.42. The stock's 50 day moving average price is $3.90 and its two-hundred day moving average price is $3.86.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in GENFIT stock. Millennium Management LLC acquired a new stake in GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned 0.33% of GENFIT at the end of the most recent reporting period. Institutional investors own 2.24% of the company's stock.
About GENFIT
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Featured Stories
Before you consider GENFIT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GENFIT wasn't on the list.
While GENFIT currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
